Literature DB >> 23537648

Interaction of the S100A6 mutant (C3S) with the V domain of the receptor for advanced glycation end products (RAGE).

Sepuru K Mohan1, Arun A Gupta, Chin Yu.   

Abstract

S100A6 is involved in several vital biological functions, such as calcium sensing and cell proliferation. It is a homodimeric protein that belongs to the S100 protein family. The receptor for advanced glycation end products (RAGE) has been shown to play a role in the progression of various disease conditions, such as diabetes and immune/inflammatory disorders. Information regarding the association of RAGE with S100 proteins at a molecular level is useful to understand the diversity of the RAGE signaling pathways. In this report, biomolecular NMR techniques were utilized for the resonance assignment of the C3S mutation in human S100A6 and characterizing its interaction with the RAGE V domain. Further binding affinity between S100A6m and the RAGE V domain was determined by isothermal titration calorimetric studies. HADDOCK was used to generate a heterotetramer model of the S100A6m-RAGE V domain complex. This model provides an important insights into the S100-RAGE cellular signaling pathway.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23537648     DOI: 10.1016/j.bbrc.2013.03.049

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  The role of S100 proteins and their receptor RAGE in pancreatic cancer.

Authors:  Estelle Leclerc; Stefan W Vetter
Journal:  Biochim Biophys Acta       Date:  2015-10-03

Review 2.  S100A6 protein: functional roles.

Authors:  Rosario Donato; Guglielmo Sorci; Ileana Giambanco
Journal:  Cell Mol Life Sci       Date:  2017-04-17       Impact factor: 9.261

3.  Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).

Authors:  Damiano Cosimo Rigiracciolo; Nijiro Nohata; Rosamaria Lappano; Francesca Cirillo; Marianna Talia; Sendi Rafael Adame-Garcia; Nadia Arang; Simone Lubrano; Ernestina Marianna De Francesco; Antonino Belfiore; J Silvio Gutkind; Marcello Maggiolini
Journal:  J Exp Clin Cancer Res       Date:  2022-06-03

4.  Tranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell Proliferation.

Authors:  Yen-Kai Huang; Ruey-Hwang Chou; Chin Yu
Journal:  J Biol Chem       Date:  2016-05-12       Impact factor: 5.157

5.  S100B as an antagonist to block the interaction between S100A1 and the RAGE V domain.

Authors:  Md Imran Khan; Yu-Kai Su; Jinhao Zou; Lee-Wei Yang; Ruey-Hwang Chou; Chin Yu
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

6.  Ezrin interacts with S100A4 via both its N- and C-terminal domains.

Authors:  Beáta Biri-Kovács; Bence Kiss; Henrietta Vadászi; Gergő Gógl; Gyula Pálfy; György Török; László Homolya; Andrea Bodor; László Nyitray
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

7.  Blocking the Interactions between Calcium-Bound S100A12 Protein and the V Domain of RAGE Using Tranilast.

Authors:  Jian Wei Chiou; Brian Fu; Ruey-Hwang Chou; Chin Yu
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

Review 8.  Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.

Authors:  Salvatore Bongarzone; Vilius Savickas; Federico Luzi; Antony D Gee
Journal:  J Med Chem       Date:  2017-05-19       Impact factor: 7.446

9.  Structural insights into calcium-bound S100P and the V domain of the RAGE complex.

Authors:  Srinivasa R Penumutchu; Ruey-Hwang Chou; Chin Yu
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

10.  Blocking the interaction between S100A9 protein and RAGE V domain using S100A12 protein.

Authors:  Revansiddha Katte; Chin Yu
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.